# Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours

> **NCT04810208** · PHASE1 · TERMINATED · sponsor: **Lidds AB** · enrollment: 6 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04810208
- **Lead sponsor:** Lidds AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-28
- **Primary completion:** 2021-10-07
- **Final completion:** 2021-10-07
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Strategic decision
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04810208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04810208, "Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04810208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*